Adjunctive therapy combining leptin with a PTP1B inhibitor (DPM-1001) enhanced glucose metabolism in type 1 diabetes (T1D) in wild-type (WT) mice to levels comparable to those of non-diabetic controls, suggesting its viability as an alternative therapeutic strategy for T1D [146]. Here, PTPN1 is linked to type 1 diabetes mellitus.